Drug Profile
CoVIg 19
Alternative Names: anti-coronavirus hIVIG - Takeda; Anti-coronavirus hyperimmune intravenous immunoglobulin - Takeda; Anti-COVID-19 Hyperimmune Globulin - Takeda; Anti-SARS-CoV-2 polyclonal H-IG - Takeda; Anti-SARS-CoV-2 polyclonal hyperimmune globulin - Takeda; COVID-19 H-IG - Takeda; CoVIg-19; TAK-888Latest Information Update: 27 Apr 2022
Price :
$50
*
At a glance
- Originator Takeda
- Developer Takeda; University of Minnesota
- Class Antivirals; Immunoglobulins; Polyclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 25 Apr 2022 Biotest AG has been acquired by Grifols
- 21 May 2021 University of Minnesota completes a phase III ITAC trial in the treatment of COVID-2019 infections in the US, Greece, UK, Denmark, Japan, Germany, Indonesia, Israel, Argentina, Nigeria and Spain (NCT04546581)
- 08 Oct 2020 Phase-III clinical trials in COVID-2019 infections in Denmark, Japan, Germany, Nigeria, Spain (IV) (EudraCT2020-002542-16) (NCT04546581)